Several novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of this disease. However, relapse is still common in many patients, and there is a need to continue exploring novel therapeutic strategies. The introduction of immunotherapies, including CAR-T cell therapy and bispecific T-cell engagers, has marked a paradigm shift in the treatment of multiple myeloma, and T-cell based therapies have shown promising outcomes.
In this exclusive podcast, leading experts Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, Nina Shah, MD, University of California, San Francisco, CA, and Thomas Martin, MD, University of California, San Francisco, CA, discuss the current challenges and future applications of T-cell engagers in multiple myeloma, the role of maintenance and transplantation, and more. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
The post T-cell engagers in multiple myeloma: current challenges and future outlooks appeared first on VJHemOnc.
